ResearcherSoonchunhyang University Hospital BucheonNo recent work listed

Sung Hee Lim

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0845-9994; OpenAlex author ID A5062157181. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 8

Papers, trials and grants by year

2021: 2 papers

Papers 2

Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicent… Co-author DOI 10.1016/j.esmoop.2021.100049 ↗
Gemcitabine and Erlotinib with or without Oxaliplatin in Previously Untreated Advanced Pancreatic Cancer: A Randomized Phase II Trial. Co-author DOI 10.3349/ymj.2021.62.8.671 ↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Jong Ho Moon · 1 shared paper, 2021 · strength 0.11
- Paper Gemcitabine and Erlotinib with or without Oxaliplatin in Previously Untreated Advanced Pancreatic Cancer: A Randomized … DOI 10.3349/ymj.2021.62.8.671 ↗
H.S. Park · 1 shared paper, 2021 · strength 0.10
- Paper Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with m… DOI 10.1016/j.esmoop.2021.100049 ↗
Jung Hun Kang · 1 shared paper, 2021 · strength 0.10
- Paper Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with m… DOI 10.1016/j.esmoop.2021.100049 ↗
Choong‐kun Lee · 1 shared paper, 2021 · strength 0.10
- Paper Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with m… DOI 10.1016/j.esmoop.2021.100049 ↗
Hye Jin Choi · 1 shared paper, 2021 · strength 0.10
- Paper Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with m… DOI 10.1016/j.esmoop.2021.100049 ↗
Woo Kyun Bae · 1 shared paper, 2021 · strength 0.10
- Paper Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with m… DOI 10.1016/j.esmoop.2021.100049 ↗
Joon Oh Park · 1 shared paper, 2021 · strength 0.10
- Paper Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with m… DOI 10.1016/j.esmoop.2021.100049 ↗
Changhoon Yoo · 1 shared paper, 2021 · strength 0.10
- Paper Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with m… DOI 10.1016/j.esmoop.2021.100049 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.